Stay updated on Dolutegravir Kinetics in Primary HIV: Clinical Trial

Sign up to get notified when there's something new on the Dolutegravir Kinetics in Primary HIV: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dolutegravir Kinetics in Primary HIV: Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:59:51.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, representing a comparison of the kinetic of HIV-RNA decay in blood plasma and seminal plasma in patients starting a triple combination regimen with dolutegravir + tenofovir DF (TDF) + emtricitabine (FTC) at the time of primary HIV infection.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:48.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying the inclusion and exclusion criteria for patients diagnosed with primary HIV infection. Previously, no information was provided about the participation criteria for collaborators and investigators.
    Difference
    11%
    Check dated 2024-05-22T21:36:41.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:57:24.000Z thumbnail image

Stay in the know with updates to Dolutegravir Kinetics in Primary HIV: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dolutegravir Kinetics in Primary HIV: Clinical Trial page.